Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 2015 Update of the Drug Resistance Mutations in HIV-1.

Literature DB >> 26713503

2015 Update of the Drug Resistance Mutations in HIV-1.

Annemarie M Wensing¹, Vincent Calvez², Huldrych F Günthard³, Victoria A Johnson⁴, Roger Paredes⁵, Deenan Pillay⁶, Robert W Shafer⁷, Douglas D Richman⁸.

Abstract

The 2015 edition of the IAS-USA drug resistance mutations list updates the figures last published in July 2014. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.

Entities: Species

Mesh：

Substances：
Anti-HIV Agents

Year: 2015 PMID： 26713503 PMCID： PMC6148920

Source DB: PubMed Journal: Top Antivir Med ISSN： 2161-5853

8 in total

1. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Authors: Peter K Quashie; Thibault Mesplède; Ying-Shan Han; Maureen Oliveira; Diane N Singhroy; Tamio Fujiwara; Mark R Underwood; Mark A Wainberg
Journal: J Virol Date: 2011-12-28 Impact factor: 5.103

2. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Authors: Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min
Journal: Lancet Date: 2013-07-03 Impact factor: 79.321

3. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.

Authors: Bluma G Brenner; Matthew Lowe; Daniela Moisi; Isabelle Hardy; Simon Gagnon; Hugues Charest; Jean Guy Baril; Mark A Wainberg; Michel Roger
Journal: J Med Virol Date: 2011-02-25 Impact factor: 2.327

4. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

Authors: Nicolas A Margot; Rebecca M Hluhanich; Gregg S Jones; Kristen N Andreatta; Manuel Tsiang; Damian J McColl; Kirsten L White; Michael D Miller
Journal: Antiviral Res Date: 2011-12-16 Impact factor: 5.970

5. Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors: Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal: Antimicrob Agents Chemother Date: 2013-03-25 Impact factor: 5.191

6. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Authors: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman
Journal: Clin Infect Dis Date: 2008-07-15 Impact factor: 9.079

7. 2014 Update of the drug resistance mutations in HIV-1.

Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman
Journal: Top Antivir Med Date: 2014 Jun-Jul

8. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Authors: Huldrych F Günthard; Judith A Aberg; Joseph J Eron; Jennifer F Hoy; Amalio Telenti; Constance A Benson; David M Burger; Pedro Cahn; Joel E Gallant; Marshall J Glesby; Peter Reiss; Michael S Saag; David L Thomas; Donna M Jacobsen; Paul A Volberding
Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 157.335

8 in total

58 in total

Review 1. CROI 2016: Advances in Antiretroviral Therapy.

Authors: Barbara S Taylor; Susan A Olender; Hong-Van Tieu; Timothy J Wilkin
Journal: Top Antivir Med Date: 2016 May-Jun

2. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.

Authors: Lalit Deshmukh; John M Louis; Rodolfo Ghirlando; G Marius Clore
Journal: Proc Natl Acad Sci U S A Date: 2016-10-17 Impact factor: 11.205

3. International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors:
Journal: J Int AIDS Soc Date: 2016-10-23 Impact factor: 5.396

4. 2017 Update of the Drug Resistance Mutations in HIV-1.

Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman
Journal: Top Antivir Med Date: 2016-12

5. 2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.

Authors: Andrew D Revell; Dechao Wang; Maria-Jesus Perez-Elias; Robin Wood; Dolphina Cogill; Hugo Tempelman; Raph L Hamers; Peter Reiss; Ard I van Sighem; Catherine A Rehm; Anton Pozniak; Julio S G Montaner; H Clifford Lane; Brendan A Larder
Journal: J Antimicrob Chemother Date: 2018-08-01 Impact factor: 5.790